Clincosm LogoSign in Get a demo

A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CM

Sponsor
Alexion Pharmaceuticals (Industry)
Overall Status
Active, not recruiting
CT.gov ID
NCT04622046
Collaborator
Eidos Therapeutics, a BridgeBio company (Industry)
22
Enrollment
13
Locations
1
Arm
42.9
Anticipated Duration (Months)
1.7
Patients Per Site
0
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This prospective study is designed to evaluate the efficacy, safety, and tolerability of ALXN2060 (also known as AG10), as well as to establish its pharmacokinetic and pharmacodynamic profile in Japanese participants with symptomatic ATTR-CM administered on a background of stable heart failure therapy.

Condition or Disease Intervention/Treatment Phase
Phase 3

Detailed Description

Participants will receive ALXN2060 for 12 months (Part A). Following the last visit (Month 12) of Part A, participants will continue the study in Part B, which will last for an additional 18 months (30 months from Day 1), during which all participants will continue to receive oral treatment with ALXN2060. Following completion of Month 30 assessments in Part B, participants will be offered the opportunity to continue to receive ALXN2060 in the Extension Period, which will last until ALXN2060 is approved in Japan or for up to 24 additional months, whichever occurs first.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
22 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Phase 3, Prospective, Multicenter, Open Label, 2-Part Study of the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of ALXN2060 in Japanese Participants With Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Actual Study Start Date :
Nov 1, 2020
Anticipated Primary Completion Date :
Nov 30, 2022
Anticipated Study Completion Date :
May 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: ALXN2060

Participants will receive ALXN2060.

Drug: ALXN2060
ALXN2060 tablets will be administered twice daily at a dose of 800 milligrams.
Other Names:
  • AG10
  • Acoramidis

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Change From Baseline To Month 12 Of Treatment In Distance Walked During The Six-minute Walk Test (6MWT) [Baseline, Month 12]

    2. All-cause Mortality And Cardiovascular-related Hospitalization Over A 30-month Period [Baseline through Month 30]

    Secondary Outcome Measures

    1. Change From Baseline To Month 30 Of Treatment In Distance Walked During The 6MWT [Baseline, Month 30]

    2. Change From Baseline To Month 12 Of Treatment In The Kansas City Cardiomyopathy Questionnaire Overall Score (KCCQ-OS) [Baseline, Month 12]

    3. Change From Baseline To Month 30 Of Treatment In The KCCQ-OS [Baseline, Month 30]

    4. Incidence Of Treatment-emergent Serious Adverse Events (SAEs) And Adverse Events (AEs) [Baseline through Month 12]

    5. Incidence Of Treatment-emergent SAEs And AEs [Baseline through Month 30]

    6. Change From Baseline To Day 28 In Transthyretin (TTR) Stabilization [Baseline, Day 28]

    7. Change From Baseline To Month 30 In TTR Stabilization [Baseline, Month 30]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    20 Years to 90 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    1. Established diagnosis of ATTR-CM with either wild-type TTR or a variant TTR genotype.

    2. History of heart failure evidenced by at least 1 prior hospitalization for heart failure or clinical evidence of heart failure without prior heart failure hospitalization manifested by signs or symptoms of volume overload or elevated pressures or heart failure symptoms that required or requires ongoing treatment with a diuretic.

    3. New York Heart Association Class I-III symptoms due to ATTR-CM.

    4. On stable doses of cardiovascular medical therapy.

    5. Completed ≥ 150 meters on the 6MWT on 2 tests prior to Day 1.

    6. Left ventricular (LV) wall (interventricular septum or LV posterior wall) thickness ≥ 12 millimeters.

    7. Biomarkers of myocardial wall stress: N-terminal pro-brain-type natriuretic pep (NT-proBNP) level ≥ 300 picograms/milliliter (pg/mL).

    Exclusion Criteria:

    1. Acute myocardial infarction, acute coronary syndrome or coronary revascularization, or experienced stroke or transient ischemic attack within 90 days prior to screening.

    2. Hemodynamic instability at screening.

    3. Likely to undergo heart transplantation within a year of screening.

    4. Current treatment with marketed drug products and other investigational agents for the treatment of ATTR-CM.

    5. Current treatment with calcium channel blockers with conduction system effects (for example, verapamil, diltiazem). The use of dihydropyridine calcium channel blockers is allowed.

    6. Confirmed diagnosis of light-chain (AL) amyloidosis.

    7. Biomarkers of myocardial wall stress: NT-ProBNP ≥ 8,500 pg/mL.

    8. Measure of kidney function, estimated glomerular filtration rate by Modification of Diet in Renal Disease formula < 30 mL/minute/1.73 meters squared.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Nagoya University Hospital Aichi Japan
    2 Kurume University Hospital Fukuoka Japan
    3 Kyushu University Hospital Fukuoka Japan
    4 Sapporo Medical University Hospital Hokkaido Japan
    5 Kitasato University Hospital Kanagawa Japan
    6 Kochi Medical School Hospital Kochi Japan
    7 Kumamoto University Hospital Kumamoto Japan
    8 Shinshu University Hospital Nagano Japan
    9 Okayama University Hospital Okayama Japan
    10 National Cerebral and Cardiovascular Center Osaka Japan
    11 Juntendo University Hospital Tokyo Japan
    12 Keio University Hospital Tokyo Japan
    13 The University of Tokyo Hospital Tokyo Japan

    Sponsors and Collaborators

    • Alexion Pharmaceuticals
    • Eidos Therapeutics, a BridgeBio company

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Alexion Pharmaceuticals
    ClinicalTrials.gov Identifier:
    NCT04622046
    Other Study ID Numbers:
    • ALXN2060-TAC-302
    First Posted:
    Nov 9, 2020
    Last Update Posted:
    Jun 30, 2022
    Last Verified:
    Jun 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Cardiomyopathies
    Amyloidosis

    Study Results

    No Results Posted as of Jun 30, 2022